Comparative Pharmacology
Head-to-head clinical analysis: ACTIFED versus CORPHEDRA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTIFED versus CORPHEDRA.
ACTIFED vs CORPHEDRA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ACTIFED contains triprolidine, a first-generation antihistamine that competitively inhibits histamine H1 receptors, and pseudoephedrine, a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and decongestion.
CorphEdra is a synthetic glucocorticoid that binds to the glucocorticoid receptor (GR), leading to transcriptional regulation of anti-inflammatory and immunosuppressive genes. It also activates the mineralocorticoid receptor (MR) with lower affinity, contributing to electrolyte and fluid balance effects.
1 tablet (pseudoephedrine HCl 60 mg, triprolidine HCl 2.5 mg) orally every 4-6 hours; maximum 4 tablets in 24 hours.
10-20 mg orally every 8 hours as needed for nasal congestion.
None Documented
None Documented
Triprolidine: 3.2 hours; Pseudoephedrine: 5–8 hours (pH-dependent: alkaline urine prolongs). Terminal half-life for clinical use typically 4–6 hours.
8-12 hours (terminal); clinical context: requires dosing every 12 hours; reduced clearance in elderly and renal impairment
Renal: 80% (20% unchanged, 60% as metabolites). Fecal: 20% (unchanged and metabolites). Active tubular secretion of pseudoephedrine.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Category C
Category C
Decongestant/Antihistamine Combination
Antihistamine/Decongestant